Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

Rationale for Ultra-Low PSA Threshold Analysis

Key Themes:

• Post hoc analysis focusing on PSA response thresholds
• Particular focus on ultra-low PSA threshold (<0.02 ng/mL)
• PSA as a surrogate biomarker in advanced prostate cancer

Expert Insights:

• Dr Shore explained the rationale for examining the ultra-low PSA threshold of <0.02 ng/mL in the ARANOTE trial.

The discussion highlighted the historical relevance of low PSA levels in predicting treatment outcomes and the potential increased sensitivity of this threshold.